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The cognitive effects of MDMA (‘Ecstasy’) are controversial, particularly in the case of acute adminis-
tration of low doses. Latent inhibition (LI) refers to the reduction in conditioning to a stimulus that has
received non-reinforced pre-exposure, an effect typically abolished by amphetamines and enhanced by
antipsychotics. LI enhancement has also been shown using the 5-HT reuptake blocker sertraline. In the
present study, the effects of MDMA (6 mg/kg, known to increase 5-HT release) were tested using 10 and
40 pre-exposures to produce weak and strong LI in controls, respectively. MDMA (injected twice, prior to
pre-exposure and conditioning) signiﬁcantly enhanced LI in that the effect was clearly demonstrated
after only 10 pre-exposures, when it was absent in the saline controls. On its own such a proﬁle of action
would be consistent with a procognitive effect of MDMA mediated by increased availability of 5-HT.
However, paradoxically the same MDMA treatment reduced LI in the 40 pre-exposures condition. This
component of action is likely attributable to MDMA’s actions on catecholaminergic systems and is
consistent with other evidence of its adverse effects. Moreover, there were small but signiﬁcant
reductions in 5-HT in medial prefrontal cortex (mPFC) and amygdala assayed 7 days post MDMA
administration (2  6 mg/kg, 24 h apart).
 2012 Elsevier Ltd. Open access under CC BY license.1. Introduction
Latent inhibition (LI) normally manifests as poorer conditioning
to a stimulus that has been previously presented without conse-
quence (Lubow and Moore, 1959). This effect is abolished by
treatment with the indirect catecholamine agonist amphetamine
(e.g., Solomon et al., 1981;Weiner et al., 1981,1984,1988; Gray et al.,
1992; Kumari et al., 1999; Nelson et al., 2011a). LI is similarly
abolished by electrolytic lesions to the medial raphe, source of the
ascending projections of the indoleamine 5-hydroxytryptamine
(serotonin, 5-HT) (Solomon et al., 1980), as well as by selective 5-
HT depletion using the neurotoxin 5,7-dihydroxytyptamine (5,7-
DHT) (Loskutova et al., 1990; Cassaday et al., 1993a; Nelson et al.,
2012), and by pharmacological treatments which reduce 5-HT
release (Solomon et al., 1978) or block its actions at postsynaptic
5-HT2 receptors (Cassaday et al., 1993b; Shadach et al., 2000).
Conversely, LI enhancement e demonstrated when LI in controls
has been systematically weakened using a reduced number of
stimulus pre-exposures e has been shown using the 5-HT reuptake
blocker (selective serotonergic reuptake inhibitor, SSRI) sertralinefax: þ44 (0)115 951 5324.
(H.J. Cassaday).
 license.(Loskutova, 1998). LI is similarly enhanced by dopaminergic anti-
psychotics (Weiner and Feldon, 1987; Feldon and Weiner, 1991;
Dunn et al., 1993), thus that the equivalent effect can be produced
by treatment with an SSRI is consistent with the procognitive
actions of SSRIs.
However, the picture is complex in that LI enhancement has also
been reported after treatment with 5-HT2 antagonists (McDonald
et al., 2003) as well as by deafferentation of the 5-HT input to the
shell subregion of the nucleus accumbens (NAc) (Nelson et al.,
2012) whereas the 5-HT2 agonist DOI has been shown to disrupt
LI (Hitchcock et al., 1997). To our knowledge, further positive effects
of treatment with pharmacological agents which mimic the actions
of 5-HT postsynaptically have yet to be demonstrated.
3,4-Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) is
a distinctive member of the amphetamine family, both in terms of
its neurochemical proﬁle and associated psychological effects. In
particular, the increased release of 5-HT produced by the controlled
administration of MDMA in therapeutic settings has been reported
to produce an anxiolytic effect and other pleasurable consequences
related to its designation as an entactogen (Bouso et al., 2008;
Johansen and Krebs, 2009). However, in animal studies, the
repeated use of MDMA (or the administration of higher doses,
Green et al., 2009) has been shown to lead to a range of acute
adverse effects from hyperthermia to death (Green et al., 2003). In
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cognitive deﬁcits have been demonstrated in regular recreational
Ecstasy users, although these are typically confounded by the
purity of the currently available supply, polydrug use and pre-
existing psychiatric problems (Fox et al., 2001; Soar et al., 2006).
Again the inﬂuence of polydrug use is difﬁcult to discount, but
psychotic episodes have also been reported in cases of long-term
recreational Esctasy consumption (McGuire and Fahy, 1991;
Marchesi et al., 2009).
Relatively high doses of MDMA (10 and 15 mg/kg, repeated
administrations) have recently been reported to be without effect
on LI in a rat model (Skelton et al., 2012), but this was study of
neurodevelopmental sensitivity which also used behavioural
procedures different from those routinely used to examine the
effects of amphetamine on LI (Weiner et al., 1981, 1984, 1988;
Nelson et al., 2011a). The present study used a selected lower dose
of MDMA (6 mg/kg i.p.) e previously demonstrated to increase
extracellular 5-HT measured in rat hippocampus by microdialysis
(Rodsiri et al., 2011)e and therefore suitable to further examine the
role of 5-HT in LI. Moreover systemic administration of 6 mg/kg in
the rat is within the range comparable to human doses (Sessa and
Nutt, 2007; Green et al., 2009). The effects of this MDMA treatment
were tested using a conditioned emotional response (CER) proce-
dure, typical of those used in LI studies, and demonstrated to be
sensitive to the effects of D-amphetamine, which as expected
abolished LI (Nelson et al., 2011a). However, the present study also
included a procedural variant (low number of stimulus pre-
exposures) demonstrated suitable to show LI enhancement
(Nelson et al., 2010, 2011b). Speciﬁcally, LI after 10 and 40 pre-
exposures was used to produce respectively weak and strong LI
in controls, and to examine the effects of MDMA thereon.
Because of the possibility that even low doses and acute
administration of MDMA can result in adverse effects which have
been argued to be related to neurotoxicity (Fox et al., 2001; Green
et al., 2003, 2009; Soar et al., 2006) tissue samples were taken for
neurochemical assay as soon as possible upon completion of the
behavioural tests.
2. Materials and methods
2.1. Subjects
72 experimentally naïve adult maleWistar rats (Charles River, UK) were caged in
pairs on a 12:12 h light/dark cycle with food and water ad libitum. They were
handled for approximately 10min per day for 1 week and then at meanweight 221 g
(range 202e250 g) were placed on water deprivation immediately prior to behav-
ioural procedures.
All procedures were carried out in accordance with the United Kingdom (UK)
Animals Scientiﬁc Procedures Act 1986, Project Licence number: PPL 40/3163.
2.2. Drug administration
MDMA HCl (Tocris, UK) was dissolved in saline at 6 mg/ml (weight calculated as
the free base) for injection (i.p.) at 1 ml/kg to administer a dose of 6 mg/kg. Control
rats were injected with the equivalent volume of saline. Drug or control injections
were administered 40 min prior to the pre-exposure and conditioning stages of the
procedure (Joseph et al., 2000). Thus all rats given MDMA received 2 doses of 6 mg/
kg with a 24 h gap between the two doses.
2.3. Behavioural apparatus
Six identical fully automated conditioning boxes, housed within sound-
attenuating cases containing ventilation fans (Cambridge Cognition, Cambridge,
UK), were used. The inner conditioning box walls consisted of plain steel
(25 cm  25 cm  22 cm high) with a Plexiglas door (27 cm  21 cm high), at the
front. The ﬂoor was a shock grid with steel bars 1 cm apart and 1 cm above the lip of
a 7 cm deep sawdust tray. A waterspout was mounted on one wall. The spout was
5 cm above the ﬂoor and connected to a lickometer supplied by a pump. Licks were
registered by a break in the photo beamwithin the spout, which also triggeredwater
delivery of 0.05 ml per lick. The waterspout was illuminated when water was
available. A loudspeaker for the presentation of auditory stimuli was set in the roof.A 5 s mixed frequency noise set at 85 dB (including background) served as the CS.
Footshock of 1 s duration and 1 mA intensity provided the unconditioned stimulus
(UCS). This was delivered through the grid ﬂoor by a constant current shock
generator (pulsed voltage: output square wave 10 ms on, 80 ms off, 370 V peak
under no load conditions, MISAC Systems, Newbury, UK). Stimulus control and data
collection was by an Acorn Archimedes RISC computer programmed in Basic with
additional interfacing using an Arachnid extension (Cambridge Cognition).
2.4. Behavioural procedure
Water deprivation was introduced 1 day prior to shaping. Thereafter, the
animals received 1hr and 15 min of ad libitum access to water in their home cage in
addition to water in the experimental boxes. The stages of the CER procedure were
as follows:
2.4.1. Pre-training
In order to initiate licking behaviour, rats were placed in the conditioning boxes
with their respective cage mate and were shaped for 1 day until all drank from the
waterspout. No data were recorded. Thereafter, animals were individually assigned
to a conditioning box for the duration of the experiment (counterbalanced by
experimental group).
There then followed 5 days of pre-training, in which rats drank in their condi-
tioning boxes for 15 min each day (timed from ﬁrst lick). The drinking spout was
illuminated throughout, but no other stimuli were presented in this phase. Latency
to ﬁrst lick was recorded to assess any pre-existing differences in readiness to drink
(prior to conditioning).
2.4.2. Pre-exposure
Animals were placed in their allocated boxes, where the pre-exposed animals
received 10 5 s CS presentations with an average inter-stimulus interval of 60 s
(PE10) or 40 5 s CS presentations with an average inter-stimulus interval of 60 s
(PE40). In order to match box exposure between the groups, the 10PE group
remained in the apparatus for a further 30 min without receiving any CS presen-
tations. The non-pre-exposed control animals were conﬁned to the apparatus for an
identical period of time (40 min) without receiving any CS presentations. Water was
not available within the box and thewaterspout was not illuminated during the pre-
exposure session.
2.4.3. Conditioning
Conditioning was conducted on the day following pre-exposure. No water was
available within the box and the waterspout was not illuminated. There were 2
conditioning trials in which the UCS footshock was delivered following termination
of the CS. The ﬁrst pairing of CS and UCS was presented after 5 min had elapsed, and
the second pairing was 5 min after the ﬁrst, followed by a further 5 min left in the
apparatus. In the absence of drinking, therewere no behavioural measures to record.
2.4.4. Reshaping
On the day following conditioning, animals were reshaped following the same
procedure as in pre-training sessions. This was in order to re-establish drinking after
conditioning.
2.4.5. Test
On the day following reshaping, the animals were placed in the conditioning
boxes and underwent an extinction test to the CS. Water was available throughout
the test and the waterspout was illuminated. Once the animals had made 50 licks,
the CS was presented for 15 min. The latency to make 50 licks in the absence of the
CS (the A period, timed from the ﬁrst lick made in each box) provided a measure of
any individual variation in baseline lick responding. This was compared with the
time taken to complete 50 licks following CS onset (B period) in a suppression ratio
(A/(A þ B)) to assess the level of conditioning to the CS, adjusted for any individual
variation in drink rate.
2.5. Design and analysis
There were 6 experimental groups run in a 3  2 independent factorial design
with pre-exposure, at levels non-pre-exposed (NPE),10 pre-exposures (10PE) and 40
pre-exposures (40PE), and drug, at levels saline and 6 mg/kg MDMA. Statistical
analysis was performed using analysis of variance (ANOVA) with alpha set at
p< 0.05 for the rejection of the null hypothesis. ANOVA of the pre-training latencies
included the additional factor of days (at 5 levels). T-tests were used to explore
signiﬁcant interactions. The dependent variables were lick latencies at pre-training
and reshaping, and the A period and suppression ratio for the test of conditioning.
Where necessary, raw latency data (time to ﬁrst lick at pre-training and reshape)
were log transformed so that their distribution was suitable for parametric analysis.
2.6. Neurochemical assay
Tissue samples were taken, adapted from an established micro-punch proce-
dure (Peleg-Raibstein et al., 2004; Nelson et al., 2010, 2011a, 2011b, 2012). Fig. 1
Fig. 2. Mean latency (log s) to drink in the experimental context at the reshape session
(S.E.M.) for previously non-pre-exposed (NPE) rats (dark grey bars) and rats given 10
(PE10; light grey bars) or 40 pre-exposures (PE40; white bars).
Fig. 1. Forebrain regions dissected for postmortem neurochemical analysis. Regions of interest were dissected by pushing micropunch needles of 1.6 mm diameter into the posterior
face of the coronal slices as indicated. Drawings are adapted from Paxinos and Watson (2005); numbers indicate distance from bregma in mm.
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injections, the behavioural control (NPE) rats (both saline- and MDMA-injected)
were humanely killed by dislocation of the neck and decapitated. The brains were
removed rapidly and were placed dorsal side up in an ice-chilled rat brain matrix
(Harvard Instruments, USA).
Using ice-chilled razor blades, three 2 mm coronal brain sections were cut. The
posterior side of the slices corresponded to approximately þ3, þ1 and 3 mm from
bregma according to the atlas of Paxinos and Watson (2005). The brain samples
were then immediately frozen on dry ice and stored at 80 C. Subsequently, the
three 2 mm coronal sections were placed posterior side up onto an ice-chilled plate.
From the ﬁrst section (þ3 mm) a 1.6 mm diameter stainless steel micropunch was
used to remove the medial prefrontal cortex (mPFC). From the second section
(þ1 mm), the 1.6 mm diameter stainless steel micropunch was also used to remove
the NAc. From the third section (3 mm) a 1.6 mm diameter stainless steel micro-
punch was used to remove the amygdala. For the NAc and amygdala samples, one
punch was used per brain hemisphere, but the mPFC punch was taken across both
hemispheres. Tissue punch samples were stored in sealed 1.5 ml Eppendorf tubes
and frozen at 80 C.
Neurotransmitter and metabolite levels in the samples were determined by
high-pressure liquid chromatography with electrochemical detection (HPLC-ED).
The tissue samples were homogenised in 0.1 M PCA solution by sonication and
centrifuged at 17,400 g for 20 min at 4 C before amine and metabolite levels were
detected using a glassy carbon electrode ﬂow cell (VT-03 Antec) with an ISAAC
reference electrode. An external standard consisting of 5-HT, DA, and metabolites, in
concentrations of 107, 0.5107 and 108 M was injected at a volume of 4 ml for
calibration. Samples were injected onto the column at 4 ml volumes.
Results were analysed using Alexys software data system. Bradford assay was
used to adjust for protein content using the pellet remaining after sample centri-
fugation, adapted from previous methods (Bradford, 1976). The signiﬁcance of
changes in neurotransmitter levels and their metabolites was determined by t-test.
3. Results
3.1. Behavioural
3.1.1. Pre-training
As would be expected, latencies to drink decreased over the
duration of pre-training, reﬂected in a main effect of days,
F(4,264) ¼ 18.36, p < 0.001. However there was no indication of any
difference in readiness to drink in the conditioning boxes as
a function of either pre-exposure or drug condition-to-be, either
overall or in interactionwith days, maximum F(2,66)¼ 1.55 p¼ 0.22.
3.1.2. Reshaping
There was no effect of pre-exposure or pre-exposure by drug
interaction on latency to drink at reshape, maximum F(2,66) ¼ 2.25p ¼ 0.11. However, there was a main effect of drug, F(1,66) ¼ 10.19,
p ¼ 0.002, reﬂecting overall shorter latencies to drink in rats
previously treated with MDMA (Fig. 2). This increased readiness to
drink is consistent with reduced contextual fear conditioning.
3.1.3. Test
Prior to presentation of the CS, rats took overall comparable
times to make 50 licks during the A period, by both drug and pre-
exposure condition, maximum F(2,66) ¼ 1.19 p ¼ 0.31. On the
suppression ratio measure of learning, which takes individual
variation in A period responding into account, there was a main
effect of pre-exposure, F(2,66) ¼ 6.29, p¼ 0.003, reﬂecting an overall
reduction in learning in consequence of prior non-reinforced
experience with the CS. However, the previous MDMA treatments
clearly affected the level of learning as there was a main effect of
drug, F(1,66)¼ 4.79, p< 0.05, as MDMA-treated rats were overall less
suppressed than vehicle-injected controls. There was also a drug by
pre-exposure interaction, F(2,66)¼ 4.39, p< 0.05, indicating that the
level of suppression to the CS differed by drug and conditioning
Fig. 3. Mean suppression ratio (S.E.M.) to the CS for previously non-pre-exposed
(NPE) rats (dark grey bars) and rats given 10 (PE10; light grey bars) or 40 pre-
exposures (PE40; white bars). Comparisons show signiﬁcant latent inhibition;
*p < 0.05; **p < 0.001 by t-test.
Table 2
Mean percentage change (S.E.M) in 5-hydroxytryptamine (5-HT), 5-
hydroxyindoleacetic acid (5-HIAA), dopamine (DA) and 3,4-dihydroxyphenylacetic
acid (DOPAC). All samples were taken from behavioural control (non-pre-exposed)
rats twice injected one week earlier with either saline or MDMA (6 mg/kg free base,
i.p.) in themedial prefrontal cortex (mPFC), nucleus accumbens (NAc) and amygdala.
*Signiﬁcant difference, p < 0.05, t-test.
5-HT 5-HIAA DA DOPAC
mPFC 31.2%* (6.5) 26.8% (11.0) þ32.5% (33.5) þ16.3% (30.6)
NAc 21.4% (7.4) 8.7% (6.4) þ4.9% (8.1) þ3.4% (9.1)
Amygdala 20.2%* (4.2) 5.4% (4.4) þ24.0% (14.6) þ31.9% (12.8)
A.J.D. Nelson et al. / Neuropharmacology 67 (2013) 331e336334group. Fig. 3 shows that (as expected) whilst LI was robust after 40
pre-exposures in the saline-injected controls, t(22) ¼ 2.57, p ¼ 0.02,
there was no evidence of LI after 10 pre-exposures in the saline-
injected controls, t(22) ¼ 1.39, p ¼ 0.18. By contrast, MDMA
appeared to potentiate LI under conditions of weak pre-exposure as
there was markedly less suppression to the CS in the PE10 relative
to the NPE group, t(22) ¼ 3.46, p ¼ 0.002. Conversely, with experi-
mental parameters (40 pre-exposures) that produced robust LI in
vehicle-injected animals, MDMA reduced LI as there was no
statistical evidence that these animals conditioned less to the CS
compared to the MDMA NPE group (t(22) ¼ 1.73, p ¼ 0.97).
3.2. Effects of MDMA administration on amine and metabolite
levels
The results of the neurochemical analysis by HPLC revealed that
one vehicle-injected animal had abnormally high levels of DA in the
mPFC (4.5 SD beyond themean) and consequently its mPFC DA data
were not included in the subsequent statistical analysis. Table 1
shows the absolute levels (pmoles/mg protein) of 5-HT, DA, 5HIAA
and DOPAC in the 3 brain regions (mPFC, NAc and amygdala) from
which samples were taken 7 days after drug. Table 2 shows the
percentage depletion relative to the vehicle-injected control levels.
There were small but signiﬁcant reductions in 5-HT levels in the
mPFC (t(22) ¼ 2.74, p < 0.05) and amygdala (t(22) ¼ 2.37, p < 0.01).
4. Discussion
The current experiment investigated the effects of acute treat-
ment with MDMA on LI, which was tested using two sets ofTable 1
Mean absolute levels (S.E.M) of 5-hydroxytryptamine (5-HT), 5-hydroxyindoleacetic acid
(pmoles/mg protein). All samples were taken from behavioural control (non-pre-exposed)
i.p.) in the medial prefrontal cortex (mPFC), nucleus accumbens (NAc) and amygdala.
5-HT 5-HIAA
Saline MDMA Saline MDMA
mPFC 0.192 (0.018) 0.132 (0.013) 0.157 (0.022) 0.115 (0.01
NAc 0.416 (0.038) 0.327 (0.031) 0.470 (0.017) 0.429 (0.03
Amygdala 0.531 (0.039) 0.424 (0.022) 0.404 (0.026) 0.382 (0.01experimental parameters (PE10 and PE40) designed to preclude
and secure the emergence of LI in vehicle-injected controls,
respectively. Consistent with previous reports, in the PE40 LI group
there was signiﬁcantly less learning compared to the NPE control
group, in other words, there was a robust LI effect in vehicle-
injected controls. In the PE10 group, vehicle-injected rats did not
show LI and conditioned to the PE stimulus at equivalent levels to
the NPE stimulus. However, after acute treatment with MDMA
(6 mg/kg i.p.) signiﬁcant LI was demonstrated in the PE10 group. In
other words, MDMA enhanced LI using experimental parameters
designed to prevent the emergence of LI in vehicle-controls (PE10).
Previously, both systemic treatments which antagonise or
deplete 5-HT (Solomon et al., 1978; Cassaday et al., 1993b; Shadach
et al., 2000) and regionally speciﬁc 5-HT depletion have been
shown to disrupt LI (Solomon et al., 1980; Loskutova et al., 1990;
Loskutova, 2001; Cassaday et al., 1993a; Nelson et al., 2012). Thus,
the demonstration here that acute treatment withMDMAenhances
LI is entirely consistent with a modulatory role of 5-HT in the
expression of LI and suggests that increased extracellular 5-HT
function potentiates LI. This suggestion is supported by the earlier
demonstration of increased LI after treatment with the SSRI ser-
traline (Loskutova, 1998).
An effect of MDMAwas also identiﬁed at the reshaping stage of
procedure. This took the form of an overall increased readiness to
recommence drinking in the experimental context after the foot-
shock conditioning on the previous day. Reduced contextual
conditioning has been widely reported after treatment with SSRIs
in other fear conditioning procedures (Inoue et al., 2011). Thus this
component of MDMA action may reﬂect increased 5-HT release.
Conversely, LI was not demonstrated after MDMA treatment in
the PE40 condition. At face value this seems a surprising result, but
other compounds can produce opposing effects on LI depending on
the experimental parameters used (Cassaday et al., 1993b;
Hitchcock et al., 1997; Shadach et al., 2000; McDonald et al., 2003;
Weiner, 2003; Barak and Weiner, 2007, 2009). Such opposing
actions may also result in apparently null effects, and may explain
why a recent study which included examination of the neuro-
developmental effects of MDMA reported no effects on LI, whereas
other cognitive effects were clearly demonstrated (Skelton et al.,
2012). However, there were also a number of important differ-
ences in the way LI and MDMA effects were assessed by Skelton
et al. (2012), principally that animals were not conditioned under(5-HIAA), dopamine (DA) and 3,4-dihydroxyphenylacetic acid (DOPAC)measured as
rats twice injected one week earlier with either saline or MDMA (6 mg/kg free base,
DA DOPAC
Saline MDMA Saline MDMA
7) 0.045 (0.004) 0.060 (0.015) 0.016 (0.003) 0.019 (0.005)
0) 5.727 (0.400) 6.099 (0.465) 2.088 (0.162) 2.160 (0.190)
8) 1.305 (0.237) 1.618 (0.191) 0.249 (0.046) 0.328 (0.032)
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any manipulation of the level of pre-exposure and after a pre-
treatment regime of higher (10 mg/kg) and repeated doses of
MDMA given at different developmental stages (Skelton et al.,
2012).
As an amphetamine, MDMA is known to promote the release of
DA (e.g. White et al., 1996) and NA (Rothman et al., 2001) as well as
5-HT, and treatment with indirect DA agonists is predicted to
disrupt LI (Solomon et al., 1981; Weiner et al., 1981; Weiner et al.,
1984, 1988; Gray et al., 1992; Kumari et al., 1999). Thus the
pattern of results obtained in the present study is likely to be
attributable to the acute effects of MDMA actions on both 5-HT and
catecholamine systems. Further work will be necessary to draw
ﬁrm conclusions as to which component of MDMA action mediates
enhanced versus abolished LI. First, if mediated by increased DA
release, the MDMA-induced abolition of strong LI should be
reversible by treatment with typical antipsychotics such as halo-
peridol (Weiner and Feldon, 1987; Weiner, 2003; Weiner and Arad,
2009). If mediated by increased 5-HT release, the MDMA-induced
enhancement of weak LI should be reversible by treatment with
5-HT antagonists. Second, the present study manipulated the level
of LI using different numbers of stimulus pre-exposures (PE10 and
PE40). An alternative method to manipulate the level of LI is to
increase the number of conditioning trials to overcome the effect of
pre-exposure and thus produce weak LI. The DA but not the 5-HT
component of MDMA action would be predicted to be susceptible
to this manipulation (Weiner, 2003; Weiner and Arad, 2009). Thus,
in contrast to the clear effect seen in the PE10 group, MDMA should
not enhance LI which has beenweakened by increasing the number
of conditioning trials.
Irrespective of the underlying mechanisms, on its own the
demonstration of enhanced LI would be consistent with a procog-
nitive effect of MDMA mediated by increased availability of 5-HT.
However, the observation that the same MDMA treatment reduced
LI in the 40 pre-exposures condition is consistent with other
evidence of its adverse effects. Moreover, we found small but
signiﬁcant reductions in 5-HT upon completion of the present
study. The MDMA administration regime was selected on the basis
of its known acute effect as an indirect 5-HT agonist but its
secondary effects would be expected to be different (Reneman
et al., 2002). Previously, at 6 mg/kg MDMA, there was no
evidence for loss of 5-HT function (measured 2e3 weeks post-
administration) after 3 administrations over the course of a single
day (Rodsiri et al., 2011). In the present study the cumulative dose
of 12 mg/kg (2  6 mg/kg, 24 h apart) produced a small but
signiﬁcant reduction in 5-HT levels in the mPFC and amygdala,
detected 1 week after the second MDMA administration. In addi-
tion to the interval to assay, the regions sampled were also different
e we selected three relatively discrete regions on the basis of their
inter-connectivity with hippocampus, as well as known involve-
ment in LI (Weiner, 2003; Weiner and Arad, 2009; Nelson et al.,
2010) e as were the strains of rats. In the Wistar strain, used in
the present study, others have reported signiﬁcant changes in the
serotonergic system 1 week post administration though after
a higher dose of 30 mg/kg MDMA (and in this case 5-HT1A receptor
density was shown to be increased by up to 30%; Aguirre et al.,
1998). On a conservative estimate, the 6 mg/kg dose used in the
present study would be equivalent to a dose of 2 mg/kg in humans
(Green et al., 2009), thus very comparable to that used therapeu-
tically without psychological or physiological adverse effects
(Mithoefer, 2006; Bouso et al., 2008). However, the signiﬁcant
reduction in 5-HT that we found 7 days subsequent to a total dose
of 12 mg/kg could be a contraindication. This ﬁnding e seen with
a relatively low dose given acutely e suggests that evidence for the
psychotherapeutic potential of MDMA should be treated withcaution (Bouso et al., 2008; Johansen and Krebs, 2009; Parrott,
2007; Sessa and Nutt, 2007).
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